Tag

Abbvie

All articles tagged with #abbvie

business5 days ago•7 min saved

AbbVie Bets $380 Million on North Chicago API Manufacturing Expansion

AbbVie announced a $380 million plan to build two new active pharmaceutical ingredient facilities at its North Chicago campus, with construction starting in spring 2026 and full operation expected by 2029. The AI-enabled manufacturing hubs will support next-generation neuroscience and obesity medicines and are part of AbbVie's broader $100 billion U.S. R&D and capital investments commitment, including plans to hire about 300 local workers.

via AbbVie News Center|

#abbvie #ai #api-manufacturing

healthcare1 month ago•6 min saved

AbbVie, U.S. Government Strike Deal to Expand Access and Invest in Domestic Pharma

AbbVie and the Trump administration announced a three-year agreement to boost U.S. access and affordability: AbbVie will offer low Medicaid prices, expand direct-to-patient access via the TrumpRx program for medicines including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID, and commit $100 billion in U.S.-based R&D and manufacturing investments over the next decade, in exchange for tariff relief and exemption from future price mandates; the deal aims to address all four of the President's drug pricing priorities, with terms kept confidential.

via AbbVie News Center|

#abbvie #drug-pricing #healthcare

business2 months ago•2 min saved

3 Stocks to Buy Now for Decades of Passive Income

The article highlights three stocks—AbbVie, Coca-Cola, and Realty Income—that are ideal for long-term passive income, emphasizing their strong dividend histories and stability, making them suitable for buy-and-hold investors seeking reliable income streams.

via Yahoo Finance|

#abbvie #business #coca-cola

finance3 months ago•2 min saved

Top High-Yield Dividend Stocks for Steady Passive Income

The article highlights three high-yield dividend growth stocks—AbbVie, Home Depot, and ExxonMobil—that offer attractive yields and have a history of increasing their payouts, making them ideal for long-term passive income generation and portfolio diversification.

via Yahoo Finance|

#abbvie #dividend-stocks #finance

business3 months ago•3 min saved

Top Dividend Growth Stocks for Long-Term Passive Income

The article highlights three high-yield dividend growth stocks—AbbVie, Home Depot, and ExxonMobil—that have a strong track record of increasing their dividends for over a decade, making them ideal long-term investments for generating passive income and diversifying a portfolio.

via The Motley Fool|

#abbvie #business #dividend-stocks

business3 months ago•4 min saved

Top Budget-Friendly Growth Stocks to Invest in Now

The article highlights three undervalued growth stocks—AbbVie, Lockheed Martin, and PayPal—that offer a combination of low valuation, growth potential, and dividends, making them attractive options for a $5,000 long-term investment.

via The Motley Fool|

#abbvie #business #dividends

business5 months ago•2 min saved

AbbVie Stock Soars on Extended Drug Exclusivity and Positive Outlook

AbbVie stock surged after securing a patent extension for Rinvoq until April 2037, protecting its revenue from generic competition and supporting its long-term growth prospects, with the drug's sales and potential new indications expected to further boost the company's performance.

via Investor's Business Daily|

#abbvie #business #patent-extension

business6 months ago•4 min saved

AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal

AbbVie is acquiring Gilgamesh Pharmaceuticals' investigational drug bretisilocin, a promising psychedelic therapy in Phase 2 trials for major depressive disorder, aiming to expand its psychiatric treatment portfolio. The drug has shown significant antidepressant effects with a shorter psychoactive duration, and the deal includes up to $1.2 billion in potential payments. This move underscores AbbVie's commitment to innovative mental health treatments.

via AbbVie News Center|

#abbvie #bretisilocin #business

business6 months ago•2 min saved

AbbVie Invests $195M to Expand U.S. Pharmaceutical Manufacturing

AbbVie announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing capacity in North Chicago, Illinois, as part of a broader plan to invest over $10 billion in the U.S. over the next decade, supporting the production of innovative medicines and creating jobs.

via AbbVie News Center|

#abbvie #api-manufacturing #business

business7 months ago•0 min saved

AbbVie Stock Rises Amid Mixed Earnings and Revenue Growth

AbbVie's stock price increased following its earnings report, driving shares higher, although specific details of the earnings or market reaction are not provided in the excerpt.

via Barron's|

#abbvie #business #earnings

business7 months ago•4 min saved

Top Dividend Stocks for Long-Term Income and Growth in 2025

The article recommends three stocks—AbbVie, Enbridge, and Realty Income—for long-term passive income, highlighting their strong dividend histories, resilience, and growth prospects, making them suitable for buy-and-hold investors seeking decades of income.

via The Motley Fool|

#abbvie #business #dividend-stocks

business8 months ago•5 min saved

AbbVie Acquires Capstan to Boost Immunology Patient Care

AbbVie is acquiring Capstan Therapeutics to enhance its immunology portfolio with Capstan's innovative in vivo RNA delivery platform and its lead asset, CPTX2309, a potential first-in-class in vivo CAR-T therapy for autoimmune diseases, aiming to transform patient care by developing treatments that can reset the immune system.

via AbbVie News Center|

#abbvie #acquisition #business

business8 months ago•5 min saved

AbbVie Acquires Capstan Therapeutics in $2.1 Billion Immunology Deal

AbbVie is acquiring Capstan Therapeutics to enhance its immunology portfolio, focusing on innovative in vivo CAR-T therapies for autoimmune diseases using Capstan's proprietary RNA delivery platform, with a potential first-in-class treatment in Phase 1 development.

via PR Newswire|

#abbvie #acquisition #business

business8 months ago•9 min saved

AbbVie’s Venetoclax Trial for Myelodysplastic Syndromes Falls Short

AbbVie's Phase 3 VERONA trial evaluating venetoclax with azacitidine for higher-risk myelodysplastic syndromes did not meet its primary endpoint of overall survival, though no new safety concerns were observed. Results will be shared at future medical events, and current venetoclax indications remain unaffected.

via AbbVie News Center|

#abbvie #business #clinical-trial

finance9 months ago•2 min saved

Top 2 Dividend Stocks to Invest In Now

The article highlights two high-quality dividend-paying stocks, RTX and AbbVie, as attractive investment options for growth and income, emphasizing their strong financials, dividend growth streaks, and resilience to inflation, making them suitable for a durable total return portfolio.

via Seeking Alpha|

#abbvie #dividends #finance